GSTP1 and cancer: The best characterized of these events, GSTP1 promoter methylation, occurs in >90% of cancers and 70% of precursor high grade prostatic intraepithelial neoplasia (PIN) lesions [13], [14] and can also be detected in blood and urine samples [15].